At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 62 enrolled
Drug / intervention
Dostarlimab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Randomized, Open-label Platform Trial Utilizing a Master Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC Participants
In Brief
A Phase 2 clinical trial evaluating Dostarlimab, Belrestotug., and 1 other intervention for Neoplasms. Completed, enrolled 62 participants across 15 sites in 6 countries.
Detailed Summary
This study is a sub-study of the master protocol 205801 (NCT03739710). This sub study will assess safety and pharmacokinetics and pharmacodynamics (PK/PD) of novel regimens (Dostarlimab plus belrestotug , and Dostarlimab plus belrestotug plus nelistotug) in participants with previously treated NSCLC.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeoplasms
CountriesCanada, France, Germany, Italy, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
Enrollment StartDec 2021
Primary CompletionMay 2024
First PostedApr 2025
TodayJul 2026
First PostedApr 14, 2025
Enrollment StartDec 23, 2021
Primary CompletionMay 2, 2024
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 1.2 years ago
Interventions
Dostarlimabdrug
Dostarlimab will be administered
Belrestotug.drug
Belrestotug will be administered
Nelistotugdrug
Nelistotug will be administered.